Stock IGC IGC PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials IGC Pharma, Inc.

Equities

IGC

US45408X3089

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.458 USD +6.51% Intraday chart for IGC Pharma, Inc. -6.53% +63.51%
Apr. 16 IGC Pharma, Inc Announces Interim Data from Its Phase 2 Clinical Trial Demonstrates Clinically Significant Reduction, Approaching Statistical Significance, in Agitation in Alzheimer?S At Week Two Compared to Placebo CI
Mar. 22 Aurora, Canopy Among Cannabis Stocks Rising After Germany Passes Partial Legalization Law MT

Valuation

Fiscal Period: March 2023 2024 2025
Capitalization 1 18.02 30.26 -
Enterprise Value (EV) 1 18.02 30.26 30.26
P/E ratio -1.54 x -2.08 x -2.86 x
Yield - - -
Capitalization / Revenue - 24.3 x 21.6 x
EV / Revenue - 24.3 x 21.6 x
EV / EBITDA - - -
EV / FCF - - -
FCF Yield - - -
Price to Book - 4.16 x -22.9 x
Nbr of stocks (in thousands) 53,077 66,063 -
Reference price 2 0.3395 0.4580 0.4580
Announcement Date 7/7/23 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2023 2024 2025
Net sales 1 - 1.243 1.399
EBITDA - - -
EBIT 1 - -10.31 -10.36
Operating Margin - -829.61% -740.6%
Earnings before Tax (EBT) 1 - -12.8 -10.53
Net income 1 -11.51 -12.8 -10.53
Net margin - -1,030.09% -752.75%
EPS 2 -0.2200 -0.2200 -0.1600
Free Cash Flow - - -
FCF margin - - -
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 7/7/23 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales 1 0.204 0.193 0.622 0.329 0.231 0.218
EBITDA - - - - - -
EBIT 1 -2.998 -2.684 -2.427 -2.603 -2.662 -2.669
Operating Margin -1,469.61% -1,390.67% -390.19% -791.19% -1,152.38% -1,224.31%
Earnings before Tax (EBT) 1 -5.589 -2.689 -2.47 -2.645 -2.704 -2.712
Net income 1 -5.589 -2.689 -2.47 -2.645 -2.704 -2.712
Net margin -2,739.71% -1,393.26% -397.11% -803.95% -1,170.56% -1,244.04%
EPS 2 -0.0900 -0.0400 -0.0400 -0.0400 -0.0400 -0.0400
Dividend per Share - - - - - -
Announcement Date 2/14/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: March 2023 2024 2025
Net Debt - - -
Net Cash position - - -
Leverage (Debt/EBITDA) - - -
Free Cash Flow - - -
ROE (net income / shareholders' equity) - - -
ROA (Net income/ Total Assets) - - -
Assets 1 - - -
Book Value Per Share 2 - 0.1100 -0.0200
Cash Flow per Share - - -
Capex 1 - 0.19 0.27
Capex / Sales - 15.37% 19.44%
Announcement Date 7/7/23 - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.458 USD
Average target price
3.25 USD
Spread / Average Target
+609.61%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IGC PHARMA, INC. Stock IGC Pharma, Inc.
+63.51% 30.26M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. IGC Stock
  4. Financials IGC Pharma, Inc.